PD-L1 – Epidemiology – Mature Markets
Clarivate Epidemiology has created a robust repository of the prevalence of biomarker- and mutation-defined treatment-eligible cancer populations. Using Clarivate’s Biomarker Epidemiology, you can now save months of time and resources researching individual tumors in which a biomarker may be significant by quickly accessing data on the size of biomarker patient populations, based on diverse eligibility criteria and treatment settings.
In addition to an extensive literature review and modeling, we leverage our in-house estimates of cancer incidence for solid and hematological malignancies. All estimates are rigorously researched and transparently reported.
PD-L1 epidemiology enables you to:
- Complete PD-L1-driven market-sizing assessments based on the size of patient populations and patient flows.
- Build the foundation of a market forecast for strategic planning for PD-L1-targeting for new and existing assets.
- Understand how the patient populations for PD-L1 will evolve over time.
- Answer any question you may have about specific subpopulations, PD-L1, and the impact of new studies.
Additional Capabilities:
- Patient-flow diagrams.
- Customizable populations and data visualization dashboards.
- Testing rates and companion diagnostic information.
- Real-world data augmentation.
- Patient journey and demographic characteristics.
- Real-world analysis of associated comorbidities and treatments.
Table of contents
- PD-L1 - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed Incidence of Cancers With PD-L1 Expression per 100,000 People of All Ages in 2021 and 2031
- Diagnosed Incidence of Cancers With PD-L1 Expression per 100,000 People of All Ages in 2021 and 2031
- Analysis of the Diagnosed Incidence of Cancers With PD-L1 Expression in 2021 by Cancer Site
- Analysis of the Diagnosed Incidence of Cancers With PD-L1 Expression in 2021 by Cancer Site
- Epidemiology Data
- Methods
- Diagnosed Incident Cases With PD-L1 Expression
- Diagnosed NSCLC Incident Cases With PD-L1 Expression Using 22C3 Antibody at TPS u2265 1%
- Diagnosed NSCLC Incident Cases With High PD-L1 Expression Using 22C3 Antibody at TPS u2265 50%
- Diagnosed Gastric Adenocarcinoma Incident Cases With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed Urothelial Carcinoma Incident Cases With PD-L1 Expression Using 22C3 Antibody at CPS u2265 10
- Diagnosed Urothelial Carcinoma Incident Cases With PD-L1 Expression Using SP142 Antibody at IC u2265 5%
- Diagnosed Triple Negative Breast Cancer Incident Cases With PD-L1 Expression Using SP142 Antibody at IC u2265 1%
- Diagnosed Triple Negative Breast Cancer Incident Cases With PD-L1 Expression Using 22C3 Antibody at CPS u2265 10
- Diagnosed Cervical Cancer Incident Cases With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed SCCHN-Larynx Cancer Incident Cases With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed SCCHN-Hypopharynx Cancer Incident Cases With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed SCCHN-Oropharynx Cancer Incident Cases With PD-L1 Expression Using 28-8 Antibody at TC u2265 1%
- Diagnosed First-Line Drug-Treatable Population With PD-L1 Expression
- Diagnosed NSCLC First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at TPS u2265 1%
- Diagnosed NSCLC First-Line Drug-Treatable Population With High PD-L1 Expression Using 22C3 Antibody at TPS u2265 50%
- Diagnosed Gastric Adenocarcinoma First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed Urothelial Carcinoma First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at CPS u2265 10
- Diagnosed Urothelial Carcinoma First-Line Drug-Treatable Population With PD-L1 Expression Using SP142 Antibody at IC u2265 5%
- Diagnosed Triple Negative Breast Cancer First-Line Drug-Treatable Population With PD-L1 Expression Using SP142 Antibody at IC u2265 1%
- Diagnosed Triple Negative Breast Cancer First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at CPS u2265 10
- Diagnosed Cervical Cancer First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed SCCHN-Larynx Cancer First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed SCCHN-Hypopharynx Cancer First-Line Drug-Treatable Population With PD-L1 Expression Using 22C3 Antibody at CPS u2265 1
- Diagnosed SCCHN-Oropharynx Cancer First-Line Drug Treatable Population With PD-L1 Expression Using 28-8 Antibody at TC u2265 1%
- Reference Materials
- Introduction
Related Market Assessment Reports
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
